A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma
Recruiting now · Phase 2 · Has a placebo group
Conditions studied: Asthma
In brief
The purpose of this study is to evaluate the effect of 2 different GP metered dose inhaler (MDI) doses relative to placebo MDI as add-on treatment to BFF MDI on lung function in participants 4 to less than 12 years of age with asthma.
Key facts
- Study ID
- NCT07525375
- Run by
- AstraZeneca
- People needed
- 69
- Starts
- 2026-04-14
- Expected to finish
- 2029-05-23
- Last updated by the study team
- 2026-04-22
Who can join
Age: 4 and older, up to 11. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Owensboro, Kentucky, United States (enrolling)
- Research Site — Long Beach, California, United States
- Research Site — San Diego, California, United States
- Research Site — Miami, Florida, United States
- Research Site — Pembroke Pines, Florida, United States
- Research Site — Lafayette, Louisiana, United States
- Research Site — Boston, Massachusetts, United States
- Research Site — Columbia, Missouri, United States
- Research Site — Cincinnati, Ohio, United States
- Research Site — Oklahoma City, Oklahoma, United States
- Research Site — Buenos Aires, Argentina
- Research Site — CABA, Argentina
- Research Site — La Plata, Argentina
- Research Site — Lanús Este, Argentina
- Research Site — Lobos, Argentina
- Research Site — Mar del Plata, Argentina
- Research Site — Mendoza, Argentina
- Research Site — Mendoza, Argentina
- Research Site — Rosario, Argentina
- Research Site — Rosario, Argentina
- Research Site — San Juan Bautista, Argentina
- Research Site — Santa Fe, Argentina
- Research Site — Brno, Czechia
- Research Site — Prague, Czechia
- Research Site — Debrecen, Hungary
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.